In today’s recent session, 0.47 million shares of the Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) have been traded, and its beta is 0.92. Most recently the company’s share price was $17.90, and it changed around -$0.99 or -5.24% from the last close, which brings the market valuation of the company to $2.26B. ARWR at last check was trading at a discount to its 52-week high of $36.72, offering almost -105.14% off that amount. The share price’s 52-week low was $17.05, which indicates that the recent value has risen by an impressive 4.75% since then. We note from Arrowhead Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.4 million shares, with the 3-month average coming to 2.04 million.
Arrowhead Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.71. If we narrow it down even further, the data shows that 0 out of 15 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 5 recommended ARWR as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Arrowhead Pharmaceuticals Inc is expected to report earnings per share of -1.18 for the current quarter.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) trade information
Instantly ARWR has been showing red trend so far today with a performance of -5.24% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 21.84 on recent trading dayincreased the stock’s daily price by 18.04%. The company’s shares are currently down -4.79% year-to-date, but still down -11.69% over the last five days. On the other hand, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is -5.34% down in the 30-day period. We can see from the shorts that 9.45 million shares have been sold at a short interest cover period of 8.94 day(s).
The consensus price target as assigned by Wall Street analysts is $27, which translates to bulls needing to increase their stock price by 33.7% from its current value. Analyst projections state that ARWR is forecast to be at a low of $24 and a high of $29.97.
Arrowhead Pharmaceuticals Inc (ARWR) estimates and forecasts
The year-over-year growth rate is expected to be 5,305.10%, up from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 11.93M in revenue for the current quarter. 7 analysts expect Arrowhead Pharmaceuticals Inc to make 18.36M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Arrowhead Pharmaceuticals Inc earnings are expected to increase by 48.37% in 2025, but the outlook is positive 11.87% per year for the next five years.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.47% of Arrowhead Pharmaceuticals Inc shares, and 79.71% of them are in the hands of institutional investors. The stock currently has a share float of 83.43%. Arrowhead Pharmaceuticals Inc stock is held by 373.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 12.7211% of the shares, which is about 15.68 million shares worth $407.61 million.
VANGUARD GROUP INC, with 9.9072% or 12.21 million shares worth $317.44 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Core S&P Midcap ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Nov 30, 2024. The former held 3.99 shares worth $71.31 million, making up 3.19% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 3.71 shares worth around $66.2 million, which represents about 2.96% of the total shares outstanding.
